We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
Cap. Flow
-$918M
Cap. Flow %
-29.36%
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.4M
2
KOD icon
Kodiak Sciences
KOD
+$42.4M
3
BTSG icon
BrightSpring Health Services
BTSG
+$40.1M
4
CLDX icon
Celldex Therapeutics
CLDX
+$33.4M
5
ILMN icon
Illumina
ILMN
+$31.7M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$74.8M
2
KRYS icon
Krystal Biotech
KRYS
+$67M
3
CGON icon
CG Oncology
CGON
+$58.5M
4
APGE icon
Apogee Therapeutics
APGE
+$54.4M
5
DHR icon
Danaher
DHR
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 83.49%
2 Miscellaneous 16.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAI
1
Caris Life Sciences
CAI
$7.24B
$211M 6.74%
7,816,142
+500,000
+7% +$14.1M
EWTX icon
2
Edgewise Therapeutics
EWTX
$4.64B
$129M 4.14%
5,210,831
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$15.7B
$107M 3.41%
751,534
-128,748
-15% -$18.7M
GKOS icon
4
Glaukos
GKOS
$10.6B
$104M 3.33%
921,979
+141,815
+18% +$13.5M
NUVL
5
DELISTED
Nuvalent
NUVL
$82.6M 2.64%
821,406
-191,576
-19% -$18.9M
XENE icon
6
Xenon Pharmaceuticals
XENE
$5.81B
$81.8M 2.62%
1,825,076
-1,779,953
-49% -$74.8M
CGON icon
7
CG Oncology
CGON
$6.59B
$77.7M 2.48%
1,870,571
-1,412,746
-43% -$58.5M
HNGE
8
Hinge Health
HNGE
$7.05B
$60.6M 1.94%
1,304,623
+394,147
+43% +$19M
ALGN icon
9
Align Technology
ALGN
$11.2B
$59.5M 1.9%
381,004
-28,687
-7% -$4.11M
KOD icon
10
Kodiak Sciences
KOD
$2.37B
$58M 1.85%
+2,072,788
New +$42.4M
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$55M 1.76%
1,187,859
-94,130
-7% -$5.16M
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$54.7M 1.75%
+2,188,320
New +$55.4M
NEO icon
13
NeoGenomics
NEO
$2.32B
$54.5M 1.74%
4,632,801
+2,861,655
+162% +$30.9M
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$5.02B
$54.3M 1.74%
2,032,021
-346,634
-15% -$8.28M
SYRE icon
15
Spyre Therapeutics
SYRE
$7.97B
$53.5M 1.71%
1,634,615
-943,789
-37% -$24.7M
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.92B
$52.5M 1.68%
1,273,935
+438,878
+53% +$17M
CLDX icon
17
Celldex Therapeutics
CLDX
$3.07B
$50.5M 1.61%
1,858,109
+1,266,420
+214% +$33.4M
INSP icon
18
Inspire Medical Systems
INSP
$1.78B
$49.9M 1.6%
540,890
-342,857
-39% -$32.8M
KRYS icon
19
Krystal Biotech
KRYS
$10.4B
$49.8M 1.59%
202,101
-318,300
-61% -$67M
ISRG icon
20
Intuitive Surgical
ISRG
$132B
$47.2M 1.51%
83,417
-46,810
-36% -$24.9M
TMO icon
21
Thermo Fisher Scientific
TMO
$230B
$46.8M 1.5%
80,725
-33,208
-29% -$18.8M
BTSG icon
22
BrightSpring Health Services
BTSG
$11.7B
$44.8M 1.43%
+1,195,786
New +$40.1M
CVS icon
23
CVS Health
CVS
$119B
$44.8M 1.43%
564,200
+125,600
+29% +$9.9M
APGE icon
24
Apogee Therapeutics
APGE
$10.2B
$43.4M 1.39%
575,067
-863,678
-60% -$54.4M
NRIX icon
25
Nurix Therapeutics
NRIX
$2.72B
$41.4M 1.32%
+2,183,864
New +$31.4M
1
2 3 4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2025 Portfolio in Review

As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.

  • Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
  • Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
  • Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
  • Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
  • Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
  • Braidwell opened 20 new positions and closed 16 in Q4 2025.
  • Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.

Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.